vzphotos/iStock Editorial by way of Getty Photos
AbbVie (NYSE:ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology medication offset a pointy gross sales decline for its blockbuster arthritis remedy Humira.
The North Chicago, Illinois-based pharma big reported $15.4B in
Source link
#AbbVie #stock #gains #company #posts #beat #ABBVNYSE
